摘要
NMDA受体过度激活在多种神经退行性疾病的发生发展过程中发挥着重要作用。虽然NMDA受体拮抗剂在动物模型取得了明显的治疗效果,但严重的副反应限制了这类化合物的临床应用;而NMDA受体NR2B亚单位分布相对集中,选择性NR2B拮抗剂有望成为更安全、有效、副作用低的一类新型药物。该文就近年来国内外NR2B拮抗剂在神经退行性疾病中的研究进展作一综述。
NMDA receptor has shown to be involved in several central nervous system disorders such as stroke, pain, parkinson＇s disease, Huntington＇s disease and epilepsy, Early studies revealed that NMDA antagonists produced adverse side effect that hampered the effort to develop NMDA antagonists. With advances in understanding the structure of NMDA receptor, NR2B antagonist is expected to be a more effective candidate with little side effect to treat these diseases. Several NR2B antagonists including CP 101, 606 are in preclinical trials in foreign countries. The present review summarizes progress in pharmacological actions of NR2B antagonists on neurodegenerative diseases.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2007年第4期433-436,共4页
Chinese Pharmacological Bulletin
